Poseida Therapeutics to Present at Two Upcoming Investor Conferences
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company, announced participation in two investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company, announced participation in two investor conferences. The Stifel 2022 Healthcare Conference is scheduled for November 16, 2022, at 10:20 am ET, while the Piper Sandler 34th Annual Healthcare Conference will take place on November 30, 2022, at 11:30 am ET. Webcasts will be available on Poseida's website, with replays accessible for 90 days post-event. Poseida focuses on innovative cell and gene therapeutics utilizing proprietary genetic engineering platforms.
Details
News Market Reaction – PSTX
The recorded move for PSTX in the trading session of this news was +0.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming investor conferences:
Stifel 2022 Healthcare Conference
Date: Wednesday, November 16, 2022
Time: 10:20am ET
Piper Sandler 34th Annual Healthcare Conference
Date: Wednesday, November 30, 2022
Time: 11:30am ET
Webcasts will be available on the Investors & Media Section of the Poseida website, www.poseida.com. A replay of each webcast will be available for approximately 90 days following each presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit www.poseida.com and connect with us on Twitter and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-two-upcoming-investor-conferences-301670922.html
SOURCE Poseida Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.